| Literature DB >> 29091707 |
Sunil Joshi1, Wei Wang1, Saeed R Khan1,2.
Abstract
Hyperoxaluria associated with renal deposition of calcium oxalate (CaOx) crystals causes renal injury and inflammation leading to number of diseases including chronic kidney disease (CKD). It is however, not been possible to separate the renal consequences of hyperoxaluria from that of CaOx crystal deposition. We decided to utilize ethylene glycol (EG) model where hyperoxaluria and CaOx crystal deposition can be separated in time. To test our hypothesis, male rats were made hyperoxaluric by administering EG, rats were euthanized and kidneys were extracted on day 14, when occasional crystal is seen in the kidneys and day 28, when all animals have developed renal CaOx crystal deposits. Total RNA was extracted for microarray analysis and genome wide analysis of differentially expressed genes was performed to investigate differences between hyperoxaluria and crystal induced alterations in the kidneys. Immunohistochemical and Hematoxylin and Eosin (H&E) staining was also done for macromolecules with significant role in stone formation. All EG fed rats became hyperoxaluric by day 7, showed a few crystal deposits on day 14, and had heavy crystal deposition by day 28. There were significant changes in the expression of genes encoding for NADPH Oxidases; macromolecular crystallization modulators; genes involved in inflammasome activation; and osteogenic marker genes. Results demonstrate major differences between hyperoxaluria and CaOx crystal induced changes in the kidneys. Injury and inflammation are mainly associated with crystal deposition indicating significant role played by crystal retention.Entities:
Mesh:
Year: 2017 PMID: 29091707 PMCID: PMC5665423 DOI: 10.1371/journal.pone.0185009
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Functional annotation charts showing differentially expressed pathways on Day 14 of highly expressed genes in the EG group.
| Category | Signaling pathway | Gene count | Percentage | p-value | Benjamini |
|---|---|---|---|---|---|
| KEGG-PATHWAY | Complement and coagulation cascades | 20 | 2.6 | 5.3E-10 | 7.8E-8 |
| KEGG-PATHWAY | ECM-receptor interaction | 18 | 2.3 | 2.8E-7 | 2.0E-5 |
| KEGG-PATHWAY | Focal adhesion | 25 | 3.2 | 2.6E-5 | 1.3E-3 |
| KEGG-PATHWAY | Leucocyte transendothelial migration | 18 | 2.3 | 4.1E-5 | 1.5E-3 |
| KEGG-PATHWAY | Cell adhesion molecules (CAMS) | 20 | 2.6 | 1.1E-4 | 3.1E-3 |
| KEGG-PATHWAY | Systemic lupus erythematosus | 13 | 1.7 | 1.4E-3 | 3.5E-2 |
| KEGG-PATHWAY | Chemokine signaling pathway | 18 | 2.3 | 4.3E-3 | 8.8E-2 |
| KEGG-PATHWAY | Natural killer cell mediated cytotoxicity | 12 | 1.6 | 9.8E-3 | 1.7E-1 |
| KEGG-PATHWAY | Prion diseases | 6 | 0.8 | 2.7E-2 | 3.7E-1 |
| KEGG-PATHWAY | Hematopoietic cell lineage | 9 | 1.2 | 3.7E-2 | 4.3E-1 |
| KEGG-PATHWAY | Pathways in cancer | 24 | 3.1 | 3.9E-2 | 4.1E-1 |
| KEGG-PATHWAY | Tight junction | 12 | 1.6 | 5.5E-2 | 5.0E-1 |
| KEGG-PATHWAY | Cytokine-cytokine receptor interaction | 16 | 2.1 | 6.2E-2 | 5.1E-1 |
| KEGG-PATHWAY | Viral myocarditis | 9 | 1.2 | 6.4E-2 | 5.0E-1 |
| KEGG-PATHWAY | Fc gamma R-mediated phagocytosis | 9 | 1.2 | 6.8E-2 | 5.0E-1 |
| KEGG-PATHWAY | Cell cycle | 11 | 1.4 | 9.2E-2 | 5.9E-1 |
| KEGG-PATHWAY | Glutathione metabolism | 6 | 0.8 | 9.9E-2 | 6.0E-1 |
The gene heading indicates number of genes mapped to an ontology category. P-values derived from Fisher’s exact test and Benjamini multiple test correlation. Gene ontology (GO) analysis and pathway analysis of genes also done using DAVID (Database for Annotation, Visualization of Integrated Discovery) enrichment analysis tool from National Institute of Allergy and Infectious diseases (NIAID), NIH.
Functional annotation charts showing differentially expressed pathways of highly expressed genes in the EG group on Day 28.
| Category | Signaling pathway | Gene count | Percentage | p-value | Benjamini | ||
|---|---|---|---|---|---|---|---|
| KEGG-PATHWAY | Hematopoietic cell lineage | 24 | 1.7 | 1.0E-7 | 1.7E-5 | ||
| KEGG-PATHWAY | ECM-receptor interaction | 23 | 1.6 | 9.5E-7 | 7.9E-5 | ||
| KEGG-PATHWAY | Cell cycle | 29 | 2.0 | 2.7E-6 | 1.5E-4 | ||
| KEGG-PATHWAY | DNA replication | 14 | 1.0 | 3.7E-6 | 1.6E-4 | ||
| KEGG-PATHWAY | Complement and coagulation cascades | 19 | 1.3 | 2.1E-5 | 7.1E-4 | ||
| KEGG-PATHWAY | Cell adhesion molecules (CAMS) | 30 | 2.1 | 2.5E-5 | 6.9E-4 | ||
| KEGG-PATHWAY | Chemokine signaling pathway | 31 | 2.2 | 1.5E-4 | 3.7E-3 | ||
| KEGG-PATHWAY | Cytokine-cytokine receptor interaction | 34 | 2.4 | 1.8E-4 | 3.8E-3 | ||
| KEGG-PATHWAY | p53 signaling pathway | 16 | 1.1 | 4.5E-4 | 8.3E-3 | ||
| KEGG-PATHWAY | Ribosome | 18 | 1.2 | 7.0E-4 | 1.2E-2 | ||
| KEGG-PATHWAY | Focal adhesion | 32 | 2.2 | 7.2E-4 | 1.1E-2 | ||
| KEGG-PATHWAY | NOD-like receptor signaling pathway | 15 | 1.0 | 7.4E-2 | 1.0E-1 | ||
| KEGG-PATHWAY | Primary immunodeficiency | 10 | 0.7 | 2.0E-3 | 2.6E-2 | ||
| KEGG-PATHWAY | Leucocyte transendothelial migration | 20 | 1.4 | 4.9E-3 | 5.7E-2 | ||
| KEGG-PATHWAY | Natural killer cell mediated cytotoxicity | 18 | 1.2 | 5.6E-3 | 6.1E-2 | ||
| KEGG-PATHWAY | Systemic lupus erythematosus | 16 | 1.1 | 1.1E-2 | 1.1E-1 | ||
| KEGG-PATHWAY | Hypertrophic cardiomyopathy (HCM) | 15 | 1.0 | 1.4E-2 | 1.3E-1 | ||
| KEGG-PATHWAY | Pathways in cancer | 40 | 2.8 | 1.7E-2 | 1.5E-1 | ||
| KEGG-PATHWAY | Gap junction | 14 | 1.0 | 2.3E-2 | 1.8E-1 | ||
| KEGG-PATHWAY | Dilated cardiomyopathy | 15 | 1.0 | 2.4E-2 | 1.8E-1 | ||
| KEGG-PATHWAY | Glutathione metabolism | 10 | 0.7 | 2.8E-2 | 2.0E-1 | ||
| KEGG-PATHWAY | Terpenoid backbone biosynthesis | 5 | 0.3 | 2.9E-2 | 2.0E-1 | ||
| KEGG-PATHWAY | Graft-versus-host disease | 10 | 0.7 | 3.1E-2 | 2.1E-1 | ||
| KEGG-PATHWAY | Toll-like receptor signaling pathway | 14 | 1.0 | 4.9E-2 | 3.0E-1 | ||
| KEGG-PATHWAY | Small cell lung cancer | 13 | 0.9 | 5.7E-2 | 3.2E-1 | ||
| KEGG-PATHWAY | Apoptosis | 13 | 0.9 | 6.6E-2 | 3.6E-1 | ||
| KEGG-PATHWAY | Viral myocarditis | 13 | 0.9 | 7.6E-2 | 3.9E-1 | ||
| KEGG-PATHWAY | Type I diabetes mellitus | 10 | 0.7 | 7.6E-2 | 3.8E-1 | ||
| KEGG-PATHWAY | Steroid hormone biosynthesis | 8 | 0.6 | 7.8E-2 | 3.7E-1 | ||
| KEGG-PATHWAY | Fc gamma R-mediated phagocytosis | 13 | 0.9 | 8.1E-2 | 3.8E-1 | ||
| KEGG-PATHWAY | Drug metabolism | 8 | 0.6 | 8.6E-2 | 3.9E-1 | ||
| KEGG-PATHWAY | Renin-angiotensin system | 5 | 0.3 | 9.2E-2 | 4.0E-1 | ||
| KEGG-PATHWAY | T cell receptor signaling pathway | 15 | 1.0 | 9.3E-2 | 3.9E-1 | ||
The gene heading indicates number of genes mapped to an ontology category. P-values derived from Fisher’s exact test and Benjamini multiple test correlation.
Common pathways between Day 14 and Day 28 of highly expressed genes in the EG group.
| KEGG # | Signaling Pathway | Day 14 | Day 28 | ||
|---|---|---|---|---|---|
| Gene Count | Percentage | Gene Count | Percentage | ||
| 1 | Hematopoietic cell lineage | 9 | 1.2 | 24 | 1.7 |
| 2 | ECM-receptor interaction | 18 | 2.3 | 23 | 1.6 |
| 3 | Cell cycle | 11 | 1.4 | 29 | 2 |
| 4 | Complement and coagulation cascades | 20 | 2.6 | 19 | 1.3 |
| 5 | Cell adhesion molecules (CAMs) | 20 | 2.6 | 30 | 2.1 |
| 6 | Chemokine signaling pathway | 18 | 2.3 | 31 | 2.2 |
| 7 | Cytokine-cytokine receptor interaction | 16 | 2.1 | 34 | 2.4 |
| 8 | Focal adhesion | 25 | 3.2 | 32 | 2.2 |
| 9 | Leukocyte transendothelial migration | 18 | 2.3 | 20 | 1.4 |
| 10 | Natural killer cell mediated cytotoxicity | 12 | 1.6 | 18 | 1.2 |
| 11 | Systemic lupus erythematosus | 13 | 1.7 | 16 | 1.1 |
| 12 | Pathways in cancer | 24 | 3.1 | 40 | 2.8 |
| 13 | Glutathione metabolism | 6 | 0.8 | 10 | 0.7 |
| 14 | Viral myocarditis | 9 | 1.2 | 13 | 0.9 |
| 15 | Fc gamma R-mediated phagocytosis | 9 | 1.2 | 13 | 0.9 |
Gene ontology (GO) analysis and pathway analysis of genes also done using DAVID (Database for Annotation, Visualization of Integrated Discovery) enrichment analysis tool from National Institute of Allergy and Infectious diseases (NIAID), NIH
Signaling pathways that are unique to day 28 with heavy CaOx crystal deposition (Nephrolithiasis) when compared with day 14 (Hyperoxaluric condition).
| KEGG Pathway | Signaling pathway | Gene Count | Percentage |
|---|---|---|---|
| 1 | DNA replication | 14 | 1.0 |
| 2 | P53 signaling pathway | 16 | 1.1 |
| 3 | Ribosome | 18 | 1.2 |
| 4 | Nod–like receptor signaling pathway | 15 | 1.0 |
| 5 | Primary immunodeficiency | 10 | 0.7 |
| 6 | Hypertrophic cardiomyopathy | 15 | 1.0 |
| 7 | Gap junction | 14 | 1.0 |
| 8 | Dilated cardiomyopathy | 15 | 1.0 |
| 9 | Terpenoid backbone biosynthesis | 5 | 0.3 |
| 10 | Graft-versus-host disease | 10 | 0.7 |
| 11 | Toll-like receptor signaling pathway | 14 | 1.0 |
| 12 | Small cell lung cancer | 13 | 0.9 |
| 13 | Apoptosis | 13 | 0.9 |
| 14 | Type-1 diabetes mellitus | 10 | 0.7 |
| 15 | Steroid hormone biosynthesis | 8 | 0.6 |
| 16 | Drug metabolism | 8 | 0.6 |
| 17 | Renin-angiotensin system | 5 | 0.3 |
| 18 | T-cell receptor signaling pathway | 15 | 1.0 |
Signaling pathways that were unique to day 14 (Hyperoxaluria) only when compared with day 28.
| KEGG Pathway | Signaling pathway | Gene Count | Percentage |
|---|---|---|---|
| 1 | Prion disease | 6 | 0.8 |
| 2 | Tight junction | 12 | 1.6 |
Relative expression of important genes in ethylene glycol (EG) fed rat vs control group, along with their p-values derived from microarray analysis and data mining.
| GENE ID | DESCRIPTION | DAY 14 | DAY 28 | ||
|---|---|---|---|---|---|
| Log Fold Change | p-value | Log Fold Change | p-value | ||
| NADPH Oxidase 4 / Renal NADPH Oxidase | 0.578 | 0.037 | 0.387 | 0.035 | |
| NADPH Oxidase 2/ Cytochrome B-245 Beta Chain | 0.952 | 0.626 | 0.518 | 0.840 | |
| P22Phox / Cytochrome B-245 Alpha Chain | 0.202 | 0.268 | 0.290 | 0.080 | |
| Glutathione Peroxidase 2 | 1.583 | 0.028 | 2.742 | 0.0001 | |
| Kidney Injury Molecule 1 | 1.870 | 0.065 | 4.390 | 0.0001 | |
| Osteopontin / Secreted Phosphoprotein 1 | 2.400 | 0.022 | 4.160 | 0.00002 | |
| Monocyte Chemoattractant Protein 1 | 0.175 | 0.638 | 1.740 | 0.201 | |
| Matrix Gla Protein | 0.705 | 0.108 | 0.807 | 0.0019 | |
| Fetuin B | 0.285 | 0.643 | 0.420 | 0.053 | |
| Tamm-Horsfall Protein / Uromodulin | -0.246 | 0.442 | -0.426 | 0.063 | |
| Lipocalin 2 | 1.807 | 0.058 | 2.178 | 0.004 | |
| Fibronectin 1 | 0.078 | 0.393 | 1.095 | 0.047 | |
| Clusterin | 1.773 | 0.041 | 2.086 | 0.0003 | |
| Cell Surface glycoprotein CD44 | 0.626 | 0.137 | 1.586 | 0.00001 | |
| Alpha-1- Microglobulin / Bikunin Precursor | 0.210 | 0.020 | 0.258 | 0.020 | |
| PYD And CARD Domain-Containing Protein | 0.422 | 0.096 | 0.393 | 0.097 | |
| NLR Family Pyrin Domain Containing 3 | 0.024 | 0.807 | 0.090 | 0.903 | |
| Interleukin 18 | 0.076 | 0.562 | 0.092 | 0.406 | |
| Thioredoxin Interacting Protein | 0.183 | 0.448 | 0.130 | 0.498 | |
| Interleukin 1 Beta | 0.194 | 0.345 | 0.799 | 0.007 | |
| Caspase 1 | -0.0041 | 0.979 | 0.371 | 0.010 | |
| Runt Related Transcription Factor 1 | 0.557 | 0.136 | 1.063 | 0.00007 | |
| Runt Related Transcription Factor 2 | 0.042 | 0.794 | 0.099 | 0.372 | |
| Keratin 18 / Cytokeratin 18 | 0.447 | 0.077 | 0.706 | 0.009 | |
| Keratin 8 / Cytokeratin 8 | 0.213 | 0.170 | 0.238 | 0.104 | |
| Vimentin | 0.237 | 0.405 | 0.412 | 0.008 | |
| Collagen Type 1 Alpha 1 Chain | 0.474 | 0.235 | 0.591 | 0.009 | |
| Collagen Type 1 Alpha 2 Chain | 0.587 | 0.100 | 0.761 | 0.005 | |
| Alkaline Phosphatase, Liver/Bone/Kidney | -0.228 | 0.147 | -0.200 | 0.227 | |
| Bone Morphogenetic Protein 7 | -0.066 | 0.627 | -0.014 | 0.852 | |
| Bone Morphogenetic Protein Receptor Type 2 | -0.118 | 0.183 | -0.428 | 0.047 | |
| Bone Morphogenetic Protein 2 | -0.031 | 0.824 | 0.339 | 0.039 | |
Most of the genes had log Fold Change values >0.3 (> 2-fold ratio differential expression). The genes include those encoding for macromolecules, various components of NLRP3 inflammasome, and osteogenic proteins. All Microarray data have been deposited with Gene Expression Omnibus (GSE-89028).